Informed Consent for External Beam Radiation Therapy (EBRT)

Section 1info grid
Section 2text block
Section 3text block
Section 4list block
Section 5list block
Section 6text block
Section 7text block
Section 8text block
Section 9text block
Section 10text block
Section 11text block
Section 12text block
Section 13signature block

Informed Consent for External Beam Radiation Therapy (EBRT)

Patient and Treatment Information

Nature and Purpose of Radiation Therapy

External beam radiation therapy (EBRT) uses high-energy X-rays or particles (protons or carbon ions in specialized centres) produced by a linear accelerator to deliver a precisely calculated dose of ionizing radiation to the tumour volume, with the goal of destroying cancer cells while maximizing preservation of surrounding healthy tissues. Modern techniques such as Intensity-Modulated Radiation Therapy (IMRT) and Volumetric Modulated Arc Therapy (VMAT) use computer-optimized beam shaping to conform the dose to the three-dimensional tumour volume and minimize radiation exposure to adjacent critical structures (organs-at-risk). Image-Guided Radiation Therapy (IGRT), using daily cone-beam CT or fiducial marker imaging, ensures accurate daily positioning of the tumour within the planned field. Stereotactic Body Radiotherapy (SBRT) or Stereotactic Ablative Radiotherapy (SABR) delivers high ablative doses in 3 to 10 fractions to small, well-circumscribed tumours. Prior to treatment, patients undergo a CT simulation scan with immobilization devices (custom thermoplastic masks, vacloc cushions) to ensure reproducible positioning. This simulation scan is used by the radiation oncology team to delineate the target volume and organs-at-risk and design the treatment plan. Treatment sessions are typically delivered Monday through Friday over the planned treatment course.

Treatment Schedule Adherence Requirement

Radiation therapy is delivered in a precisely designed series of fractions (treatment sessions). The biological effectiveness of fractionated radiotherapy depends on consistent daily delivery without unplanned gaps. Missing treatment appointments without medical justification reduces the overall biological dose delivered to the tumour and is associated with inferior local tumour control rates. If you are unable to attend a scheduled session, you must notify the radiation therapy department immediately so that a make-up fraction can be scheduled to maintain the planned overall treatment time. Serious or prolonged illness preventing attendance will be managed by the radiation oncology team on an individual basis.

Material Risks and Potential Side Effects

Fatigue: the most universal radiation side effect, accumulating progressively over the treatment course and peaking in the last 1 to 2 weeks. Usually resolves over 4 to 8 weeks following treatment completion. Severe fatigue may require activity modification and supportive care.
Skin reactions in the radiation field: erythema (redness), dry desquamation (peeling), and moist desquamation (weeping skin breakdown) in approximately 40 to 80 percent of patients receiving breast or head and neck radiation. Managed with non-perfumed emollients, avoid sun exposure, and wound care nursing.
Mucositis (head and neck radiation): painful inflammation and ulceration of the oral mucosa, oropharynx, and hypopharynx causing dysphagia, odynophagia, and nutritional impairment. Approximately 80 percent of head and neck radiation patients require nutritional support (dietary supplements or nasogastric tube feeding) during treatment.
Bowel toxicity (pelvic radiation): acute and late radiation proctitis causing rectal urgency, increased bowel frequency, rectal bleeding, and diarrhea. Severe late radiation bowel injury (bowel obstruction, fistula) is rare with modern IMRT techniques, occurring in less than 2 percent.
Urinary toxicity (prostate/bladder/pelvic radiation): acute radiation cystitis causing urinary frequency, urgency, dysuria, and haematuria. Late radiation-induced bladder damage, including reduced bladder capacity and haemorrhagic cystitis, occurs in 2 to 5 percent of patients.
Pulmonary toxicity (thoracic radiation): radiation pneumonitis causing cough, dyspnoea, and fever developing 4 to 12 weeks after completing lung or breast radiation. Treated with corticosteroids in symptomatic cases. Progression to radiation fibrosis causing chronic pulmonary impairment occurs in a subset of patients.
Neurological toxicity: radiation to the brain or spinal cord may cause acute swelling (requiring dexamethasone), radiation necrosis (1 to 5 percent of patients with high-dose brain radiation), cognitive decline from whole brain radiation, or radiation-induced spinal cord injury (myelopathy), an uncommon but serious late complication.
Gonadal toxicity and infertility: pelvic radiation may cause premature ovarian failure, menopausal symptoms, and permanent infertility. Testicular radiation causes azoospermia. Ovarian transposition and sperm banking should be discussed before pelvic radiation in patients of reproductive age.
Secondary radiation-induced malignancy: radiation exposure carries a small but real lifetime risk of inducing a second primary cancer within or adjacent to the radiation field. The absolute risk is estimated at 1 in 500 to 1 in 1,000 patients at 20 to 30 years follow-up, and is substantially outweighed by the benefit of treating the primary tumour.

Alternatives to Radiation Therapy

Surgery: depending on tumour site and stage, surgical resection may be an equivalent or superior alternative; risks, recovery, and functional outcomes differ and should be compared with the treating multidisciplinary team.
Systemic therapy alone (chemotherapy, targeted therapy, immunotherapy): in certain tumour types, systemic therapy may control disease without local radiation.
Active surveillance or watchful waiting: appropriate in select low-risk tumours where the natural history favours delayed intervention without immediate radiation.

Expected Benefits

The expected benefit of radiation therapy depends on the treatment intent. With definitive or adjuvant intent, the goal is to eradicate local or regional cancer cells, reduce the risk of local recurrence, and in many tumour types, improve long-term survival. With palliative intent, radiation provides effective symptom relief (pain from bone metastases, bleeding, airway obstruction) often within 1 to 4 weeks of treatment. The specific expected response rates, local control rates, and survival outcomes based on your tumour type and clinical scenario have been discussed with you by your radiation oncologist.

Fertility Preservation and Gonadal Shielding

If you are of reproductive age and pelvic or abdominal radiation is planned, your radiation oncologist must discuss fertility preservation options with you before simulation. Options include sperm banking for male patients, oocyte or embryo cryopreservation for female patients, and ovarian transposition (oophoropexy) surgery to move ovaries outside the radiation field. A referral to a reproductive medicine specialist can be arranged urgently. Gonadal shielding will be applied where anatomically feasible without compromising target coverage.

Right to Refuse or Withdraw Consent

You have the right to refuse radiation therapy or withdraw your consent at any time without penalty or adverse effect on your access to other oncology treatments or supportive care. Missing or discontinuing sessions mid-course will be discussed with your oncologist, as incomplete treatment may reduce tumour control without achieving full disease benefit.

Questions and Understanding Confirmation

I have been informed of the radiation therapy technique, fractionation schedule, expected acute and late side effects specific to my treatment site, and the schedule adherence requirements. I have been advised about fertility preservation options. All my questions have been answered to my satisfaction.

Language Access and Interpreter Services

If English is not your primary language or if you require assistance communicating, a qualified medical interpreter is available at no cost. Please notify your radiation oncology team before signing this document.

Copy of Consent Acknowledgment

I acknowledge that I have been offered a signed copy of this informed consent form for my own records.

Patient Authorization

I have been informed of the planned radiation therapy technique, the fractionation schedule, field-specific side effects (acute and late), and the risk of secondary malignancy. I understand the critical importance of attending every scheduled session. I consent to proceed with radiation therapy as planned and to report any significant new symptoms promptly to the radiation oncology team.

Signatures and Verification

Patient Signature
Radiation Oncologist Signature
Witness Signature
Date and Time
Document ID: CC-PENDING
CONSENTCOLLECT